Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
- TransCon CNP delivered continuous exposure of CNP at target levels for seven days with a single subcutaneous administration - - TransCon CNP phase 1 results reinforce preclinical data and support target product profile - COPENHAGEN, Denmark, Nov. 28, …